Abstract:Background The combination of dasatinib and blinatumomab represented a chemotherapy-free treatment approach, which had been employed in the management of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). A recent study demonstrated that combination therapy of ponatinib with blinatumomab may achieve better efficacy, with a complete molecular response (CMR) rate of 87%. However, some patients required dose reduction or even discontinuation of ponatinib for the occurrence of cardiovascular adverse events. Olverembatinib, a potent third-generation tyrosine kinase inhibitor (TKI), showed both favorable tolerability and significant efficacy in patients with TKI-resistant chronic myeloid leukemia. But its effectiveness in ALL remained unaddressed. Our recent study, a frontline combination of Olverembatinib and PDT-ALL-2016 regime in Ph+ALL, had shown a promising outcome, achieving a complete molecular response (CMR) rate of 84.6% at day 90. Herein, we explored the clinical efficacy of the frontline combination of Olverembatinib and blinatumomab for the treatment of Ph+ and ABL-class Ph-like ALL. Methods From April 2022 to May 2023, 13 patients with Ph+/Ph-like ALL treated with olverembatinib (40mg once every other day) and blinatumomab (administered for a total of 2 weeks followed by 2 weeks of break) were enrolled (Figure 1a). Two patients (15.4%, 2/13) were in Ph-like ALL group with TEL-ABL and EBF1-PDGFRB fusion gene. Five patients (38.5%, 5/13), with a median age of 58 years old, were received ≥2 cycles and eight patients (61.5%, 8/13), with a median age of 34.5 years old, were treated with 1 cycle before HSCT. Result With a median follow-up of 7 months, all patients (100%, 13/13) achieved complete remission (CR) after one cycle of treatment. Among them, nine patients (72.7%, 9/13) achieved complete molecular remission (CMR) after one cycle, and ten patients (90.1%, 10/13) after two cycles. Notably, all patients (100%, 13/13) achieved CMR within three months of olverembatinib and blinatumomab treatment (Figure 1b). The 6-month overall survival (OS) rate was 100% and the 6-month event-free survival (EFS) rate was 87.5% (Figure 1 c and d). One patient with ABL mutation EE255V died due to relapse after HSCT. The regimen was overall well tolerated. For hematologic toxicity, one patient (7.7%, 1/13) experienced grade 1 neutrophil decrease. Regarding non-hematologic toxicity, five patients (38.4%, 5/13) developed infections during treatment, including COVID-19 and herpes zoster. Five patients (38.4%, 5/13) experienced decreased levels of immunoglobulins. Ten patients (76.9%, 10/13) experienced grade 1 cytokine release syndrome (CRS). Importantly, there were no interruptions in dosing of olverembatinib during treatment while no cardiovascular adverse events were observed. Conclusion This is the first report on the combination of olverembatinib with blinatumomab for the treatment of Ph+/Ph-like ALL. Among the 13 patients enrolled, a notable rate of CR and CMR was observed, which holds promise for improved long-term survival. Additionally, the combination of olverembatinib and blinatumomab exhibited minimal adverse events, both in terms of hematologic and non-hematologic toxicities. Notably, fewer cardiovascular adverse events that required discontinuation of treatment compared to ponatinib were observed. Altogether, these findings strongly indicated that combination therapy of olverembatinib with blinatumomab has the potential to become a new standard of care in the frontline treatment of Ph+/Ph-like ALL. However, further clinical trials are needed to definitively establish the efficacy of this treatment approach and validate the potential benefits. This research was supported by the National Natural Science Foundation of China(NFSC82170163, 81970147), Clinical Study of Nanfang Hospital(LC2016ZD009/2019CR012).

Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression

Abivertinib Synergistically Strengthens the Anti‐leukemia Activity of Venetoclax in Acute Myeloid Leukemia in a BTK‐dependent Manner

Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed

Venetoclax-ponatinib for T315I/compound-mutated Ph Plus Acute Lymphoblastic Leukemia

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Gilteritinib Plus Azacitidine and Venetoclax for FLT3-ITD Mutated Relapsed/refractory Acute Myeloid Leukemia

High-Throughput Drug Screen for Potential Combinations With Venetoclax Guides the Treatment of Transformed Follicular Lymphoma

Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances anti-leukemia activity of venetoclax in acute myeloid leukemia.

Synergistic Effect of Venetoclax and Bendamustine in Early T-cell Precursor Acute Lymphoblastic Leukemia

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation

Combination of Venetoclax and Cudc-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed

Frontline Combination of 3 rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL Patients

Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

BCL-2 inhibitor synergizes with PI3K inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia

A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas with MYC and BCL2 Rearrangements

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance